Wanda Cromlish

TL;DR: In this article, the mouse homolog of the gene encoding PTP-1B yielded healthy mice that, in the fed state, had blood glucose concentrations that were slightly lower and concentrations of circulating insulin that were one-half those of their PTP−1B+/+ littermates.

TL;DR: Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724 and was more selective in whole cell assays than the published Cat K inhibitors balicatib and relac atib.

TL;DR: The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described, essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due toCOX-1 inhibition.

TL;DR: Rofecoxib is a novel COX-2 inhibitor with a biochemical and pharmacological profile clearly distinct from that of current nonsteroidal anti-inflammatory drugs and represents a new therapeutic class of anti- inflammatory agents for the treatment of the symptoms of osteoarthritis and rheumatoid arthritis with improved gastrointestinal tolerability.

TL;DR: The time‐dependent inhibition by DFU was decreased by co‐incubation with arachidonic acid under non‐turnover conditions, consistent with reversible competitive inhibition at the COX active site.